

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

One potential equality issue was raised during consultation on the draft scope, but this did not result in any changes being made to the draft scope.
---

The Arrhythmia Alliance (A-A), The Heart Rhythm Charity explained that <i>“Areas of socio-economic depravity will affect patient access to a new treatment, in terms of the patient knowing/being able to access care”</i> .
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

None
------

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

None
------

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?
No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?
N/A

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
This issue has been included in the summary table in the ACD.

**Approved by Associate Director (name):** Janet Robertson

**Date:** December 2011

### **Final appraisal determination**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
None

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?
No	

3.	If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?
No	

4.	Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
N/A	

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 18 May 2012